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Abstract
Purpose: In February 2008, the US Food and Drug Adminis-
tration (FDA) granted accelerated approval for bevacizumab for
metastatic breast cancer. After public hearings in July 2010, and
June 2011, the FDA revoked this approved indication in Novem-
ber 2011, on the basis of additional evidence regarding its risk/
benefit profile. The Centers for Medicare and Medicaid Services,
local Medicare contractors, and commercial payers varied in
their stated intentions to cover bevacizumab after FDA’s regula-
tory actions. We examined payer-specific trends in bevacizumab
use after the FDA’s regulatory actions.
Methods: We used outpatient medical claims compiled by IMS
Health to evaluate trends in bevacizumab use for breast cancer
for Medicare-insured and commercially insured patients (N 
102,906) using segmented regression. Given that Medicare cov-
erage policies may vary across regional contractors, we esti-
mated trends in bevacizumab use across 10 local coverage
areas. In a sensitivity analysis, we estimated trends in bevaci-
zumab use for breast cancer compared with trends in use for
lung cancer using difference-in-differences models.
Results: Among chemotherapy infusions for breast cancer,
bevacizumab use decreased from 31% in July 2010, to 4% in
September 2012. Use decreased by 11% among commercially
insured and 13% among Medicare-insured patients after July
2010 (interaction P  .68) and continued to decline by 9% per
month (interaction P  .61). We observed no contractor-level
variation in bevacizumab use among Medicare beneficiaries.
During the same period, bevacizumab use for lung cancer was
stable.
Conclusion: Although insurers varied in public statements re-
garding coverage intentions, bevacizumab use declined similarly
among all payers, suggesting that provider decision making,
rather than payer-specific coverage policies, drove reductions.
Introduction
Bevacizumab is an infused anticancer therapy that was first
approved by the US Food and Drug Administration (FDA) in
2004 for use in metastatic colorectal cancer.1 Since its initial
approval, bevacizumab has also received approval for use alone
or in combination for treating glioblastoma, non–small-cell
lung cancer, and renal cell cancer.2-4 In February 2008, the
FDA granted accelerated approval to expand use of bevaci-
zumab to include first-line therapy of metastatic, human epi-
dermal growth factor receptor 2–negative breast cancer.5,6 The
accelerated approval was given on the basis of initial promising
results that were related to progression-free survival in ECOG
(Eastern Cooperative Oncology Group) trial E2100, when be-
vacizumab was added to docetaxel.7
As a condition of the approval, the FDA required that the
manufacturer provide additional data to confirm the clinical
benefits of bevacizumab with respect to progression-free and
overall survival. Evidence from these follow-up studies failed to
demonstrate anticipated overall survival benefits of bevaci-
zumab for breast cancer beyond the benefits provided by che-
motherapy alone; the evidence also highlighted increased risks
of severe adverse effects.5,6,8-10 In July 2010, in light of the new
data, the FDA’s Oncologic Drugs Advisory Committee
(ODAC) voted 12 to one to remove bevacizumab’s labeled
indication for treating metastatic breast cancer. This meeting
was followed by a hearing in June 2011, in which the ODAC
voted unanimously (six to zero) to withdraw the approval of the
breast cancer indication. In November 2011, the FDA formally
withdrew bevacizumab’s breast cancer indication.11-13
Major payers, including Medicare and commercial health
plans, varied in their public responses regarding their intended
coverage policies after the FDA’s removal of bevacizumab’s
breast cancer indication. For example, one large private insurer,
Blue Shield of California, announced their intention to stop
paying for bevacizumab for breast cancer after the June 2011
hearing,14 but after outcry from consumer groups, they quickly
softened their public stance, noting that bevacizumab would be
covered for patients on a case-by-case basis.15
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At the same time, the Centers for Medicare and Medicaid
Services (CMS) announced their intention to continue to cover
bevacizumab for breast cancer, regardless of the FDA’s decision
to withdraw approval.12,16 Medicare, although a federal
program, allows coverage for some services to differ across
Medicare claims processing contractors, potentially creating
variation in product use even within the Medicare pro-
gram.17-22 In the case of bevacizumab, there was noted variation
in stated coverage policies between local Medicare claims pro-
cessing contractors after the indication withdrawal.23
Previous research has documented that there were signifi-
cant decreases in bevacizumab use over time, with large declines
coinciding with the timing of each advisory committee meeting
or regulatory action beginning in June 2010.24 It is unknown
whether or to what extent public statements regarding intended
coverage translated into differences in the use of bevacizumab
for breast cancer by payer or local coverage area. We examined
Medicare- and commercial insurer–specific trends in bevaci-
zumab use to explore the role of coverage policies in reducing
bevacizumab use for breast cancer after the July 2010 ODAC
meeting and the FDA’s subsequent indication withdrawal.
Methods
Data Source
We used IMS Health LifeLink private practice provider medi-
cal claims database from January 2007 to September 2012 for
all analyses. This administrative data source compiles outpa-
tient medical claims submitted by private practitioners for re-
imbursement by insurers using the standardized billing form
CMS-1500.25 IMS Health receives approximately one billion
claims per year from physicians working in the United States.
These data are available in near real-time; approximately 95%
of claims are received within 21 days of electronic submission
for payment by the provider.
Sample Selection
We included claims for in-office–administered chemotherapy
that included International Classification of Diseases ninth edi-
tion (ICD-9) codes for breast cancer (174.x) between January
2007 and September 2012. Because bevacizumab was widely
used for the treatment of macular degeneration and diabetic
retinopathy during this time period, we included only chemo-
therapy claims for which breast cancer was the primary diagno-
sis code (N  125,765). We excluded individuals living outside
of the contiguous United States (n  42). We also excluded
individuals whose primary payer was not Medicare or a com-
mercial health plan because these two insurance categories cov-
ered 82% of the individuals meeting our study criteria and were
the focus of public statements regarding coverage determina-
tions, which was the primary focus of this study (n  22,817;
n  8,460 in Medicaid and n  14,357 covered by “other”
insurance). This resulted in 102,906 individuals with breast
cancer diagnoses for our analysis.
We separated individuals into two payer categories—Medi-
care or commercial insurance—to determine whether there was
a differential impact of the FDA’s indication withdrawal by
payer. Additionally, because Medicare coverage policies may
vary by local coverage areas, we divided states into coverage area
regions as described in the Local Coverage Areas section to
ensure that we did not mask regional changes in use, should
they have existed.
Local Coverage Areas
We defined Medicare local coverage areas at the state level. We
used the CMS Web site to identify contractors by state.26 We
searched for notices of contract awards during the study period
and abstracted the Medicare Administrative Contractor (MAC)
jurisdictions affected, the date of planned implementation, and
the previous MAC that managed claims for each affected state.
Award implementation dates were used to assign local coverage
area by year, with the contractor that serviced the state for the
majority of the year assigned as the MAC. We assumed that the
date of implementation was that announced in the award no-
tice, unless documentary evidence indicated otherwise.
Analysis
We estimated changes in monthly bevacizumab use as a pro-
portion of all injectable anticancer therapy use between January
2007 and September 2012. To estimate changes in bevaci-
zumab use during the study period, we used an interrupted time
series design.27 We considered the first ODAC meeting at the
FDA to be the month of the intervention (July 2010) because
other evidence suggests that use began declining steeply at this
time.24 We also included a study month indicator to account
for the base trend in bevacizumab use before the ODAC meet-
ing (1 to 69 for time between January 2007 and September
2012) and a postintervention month indicator to estimate the
postintervention change in trend (months 44 to 69). We tested
interactions between payer and time to determine if there were
significant differences in responses by payer. These models were
estimated using generalized estimating equations with a log link
and binominal distribution to generate risk and risk ratios di-
rectly and to adjust SEs for repeated measures.
Because Medicare coverage policies may vary by local cover-
age area,20 we also estimated changes in bevacizumab use for
breast cancer over time by local coverage area to determine
whether there were regional contractor–level differences in re-
sponsiveness to the labeled indication withdrawal. Similar to
the previous models, we used generalized estimating equations
with a log link and binomial distribution. We included the local
coverage area variable as a class-level indicator and tested the
independent and interactive effects of the local coverage area
variable with each of the time-related variables. Significant in-
teractions between local coverage areas and time would suggest
that there was variation in bevacizumab use across areas within
Medicare.
Sensitivity Analyses
Because we were concerned that changes in the use of bevaci-
zumab over time, independent of regulatory actions and poten-
tial coverage changes, could influence our findings, we also used
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a difference-in-differences model to evaluate trends in use for
breast cancer in comparison with trends in use for lung cancer
(n  78,671 patients with primary ICD-9 diagnosis code
162.x). We selected lung cancer because bevacizumab received
FDA approval for the treatment of metastatic, nonsquamous
non–small-cell lung cancer in 2006,28 and the lung cancer in-
dication did not change during the study period. Therefore, we
expected that payer decisions with respect to limiting coverage
for bevacizumab would be targeted toward use for breast cancer
and would have little effect on cancer in other sites, such as lung
cancer.
Results
Among the 102,906 individuals with breast cancer who used
chemotherapy and were included in our sample, 70.9% were
commercially insured and 29.1% were Medicare insured; the
mean age was 58.3 years (standard deviation,12.6; Appendix
Table A1, online only). As shown in Figure 1, bevacizumab as a
proportion of all chemotherapy use for breast cancer declined
from a peak of 38% in July 2009 and 31% in July 2010 to only
4% by September 2012, whereas bevacizumab use for lung
cancer declined only slightly during this period, from 47% to
40% (data not shown). As indicated in Figure 1, there were no
differences in the baseline use of bevacizumab for breast cancer
by payer; Medicare and commercial enrollees received bevaci-
zumab for approximately 26% of their infused anticancer treat-
ments during 2007 through mid-2010, before the advisory
period.
In the interrupted time series analysis stratified by payer
(Table 1), bevacizumab use declined among commercially in-
sured individuals by 11% after the July 2010 advisory commit-
tee meeting (risk ratio [RR], 0.89; 95% CI, 0.84 to 0.95) and by
an additional 9% per month subsequently (monthly decline
from August 2010 through September 2012; RR, 0.91; 95%
CI, 0.91 to 0.92). Similarly, among Medicare beneficiaries,
there was a 13% decrease in use after July 2010 (RR, 0.87; 95%
CI, 0.80 to 0.96) and an additional 9% monthly decline during
the following months (RR, 0.91; 95% CI, 0.90 to 0.92).
Finally, when considering the impact of Medicare local cov-
erage area on the use of bevacizumab during the study period,
we observed no evidence of variation in the responses to the
regulatory actions or potential coverage changes (P  .05 for all
interactions; data not shown).
In a sensitivity analysis comparing time trends in the use of
bevacizumab for individuals with breast cancer versus those
with lung cancer, there was only a slight decline in bevacizumab
use among patients with lung cancer. In particular, we observed
no change in the use of bevacizumab after the ODAC meeting
in July 2010 (RR, 1.01; 95% CI, 0.97 to 1.04) and only a small
decrease in monthly use after that time (RR, 0.99; 95% CI,
0.99 to 0.99; Table 2). Estimates from the difference-in-differ-
ences model showed that bevacizumab use among patients
treated for breast cancer decreased by an additional 12% during
the intervention period and by an additional 8% per month in
the postintervention period above that observed for patients
treated for lung cancer.
Discussion
Although payers varied in their public statements regarding
their intentions to cover bevacizumab for breast cancer,14,16
bevacizumab use decreased rapidly among patients with both
commercial insurance and Medicare after the FDA’s first
ODAC meeting in July 2010 through late 2012. Importantly,
these declines were not seen among individuals with diagnoses
for lung cancer, suggesting that physicians were likely respond-
ing to the negative risk-benefit profile and potential for cover-
age changes for breast cancer–specific use. Furthermore,
although Medicare contractors varied in their stated intent to
cover bevacizumab,23 we did not observe such variation. Previ-
ous studies exploring the role of local coverage–area group pol-
icies have seen little difference in physician behavior and use of
services, suggesting that the lack of variation by contractors
could have been anticipated in this case.22,29,30
One possible explanation for the lack of observed varia-
tion is that coverage policies were not the primary drivers of
























































































































Figure 1. Trends in bevacizumab use for breast cancer as a proportion of infused chemotherapies by payer. Regulatory actions identified by vertical
lines: February 2008, US Food and Drug Administration (FDA) approval for metastatic breast cancer. July 2010, FDA Oncologic Drugs Advisory
Committee (ODAC) meeting on evidence supporting breast cancer indication withdrawal. December 2010, FDA announces intent to withdraw
bevacizumab’s breast cancer indication. June 2011, Second ODAC meeting. November 2011, FDA indicates withdrawal.
Payer Differences in Bevacizumab Use
JULY 2015 • jop.ascopubs.org 315Copyright © 2015 by American Society of Clinical Oncology
use because of their concerns regarding the safety and effec-
tiveness of this agent for their patients. Given the timing of
declines in use, physicians seemed to respond quite rapidly
to efficacy and safety data that were presented at advisory
committee meetings before the FDA’s formal withdrawal of
bevacizumab’s indication. In fact, several other studies have
shown that physicians respond rapidly to new information
related to safety and effectiveness of therapies used among
patients with cancer.24,31,32 This responsiveness to regula-
tory actions may be unique to cancer-related therapies, given
the rapid advances in treatment and the preeminence of
clinical guidelines in this medical area. Alternatively, physi-
cian’s rapid responses could also be a result of their antici-
pation of changes in bevacizumab coverage. Private or
community-based practices may have been more financially
vulnerable if payers changed their coverage policy for bev-
acizumab, making it more difficult for physicians to recoup
the costs of this high-priced therapy.
Second, changes in pharmaceutical product use during pe-
riods after regulatory actions can be driven by many factors,
aside from insurer coverage policies.33 These factors include
changes in pharmaceutical promotion by manufacturers, dis-
semination of drug risk information through the media and lay
press, peer-reviewed publications, physician-patient communi-
cation, and modification of treatment guidelines, among oth-
ers. Additionally, the data on which regulatory decisions are
based may also be used by clinicians and payers to shift practice
patterns even before formal regulatory actions are made. Al-
Table 1. Interrupted Time Series Results Assessing Change in Bevacizumab Use for Breast Cancer, Combined and Stratified
by Payers
Insurers Risk Ratio 95% CI P
All insurers
Monthly change (months 1-69)* 1.01 1.01 to 1.01  .001
Medicare v commercial 0.92 0.82 to 1.03 .14
Intervention (July 2010)† 0.89 0.84 to 0.95  .001
Monthly change after intervention (months 44-69)‡ 0.91 0.91 to 0.92  .001
Monthly change  Medicare interaction 1.00 1.00 to 1.01 .02
Intervention (July 2010)  Medicare interaction 0.98 0.88 to 1.09 .68
Monthly change after intervention (months 44-69) interaction 1.00 0.98 to 1.01 .61
Stratified by Payers
Commercial payers
Monthly change (months 1-69)* 1.01 1.01 to 1.01  .001
Intervention (July 2010)† 0.89 0.84 to 0.95  .001
Monthly change after intervention (months 44-69)‡ 0.91 0.91 to 0.92  .001
Medicare
Monthly change (months 1-69)* 1.02 1.01 to 1.02  .001
Intervention (July 2010)† 0.87 0.80 to 0.96  .001
Monthly change after intervention (months 44-69)‡ 0.91 0.90 to 0.92  .001
NOTE. Source: IMS Health LifeLink from January 2007 to September 2012, IMS Health. All rights reserved.
* Time represents months from January 2007 to September 2012.
† Intervention represents time after July 2010.
‡ Time after intervention represents months beginning after July 2010 to September 2012.
Table 2. Difference-in-Differences Results Assessing Change in Bevacizumab Use for Breast Cancer, Compared With Change in
Use for Lung Cancer
Parameter Risk Ratio 95% CI P
Breast cancer 0.59 0.55 to 0.63  .001
Monthly change (months 1-69)* 1.01 1.01 to 1.01  .001
Intervention (July 2010)† 1.01 0.97 to 1.04 .76
Monthly change after intervention (months 44-69)‡ 0.99 0.99 to 0.99  .001
Monthly change  breast cancer interaction 1.01 1.00 to 1.01  .001
Intervention (July 2010)  breast cancer interaction 0.88 0.83 to 0.94  .001
Monthly change after intervention (months 44-69)  breast cancer interaction 0.92 0.92 to 0.93  .001
NOTE. Source: IMS Health LifeLink from January 2007 to September 2012, IMS Health. All rights reserved.
* Time represents months from January 2007 to September 2012.
† Intervention represents time after July 2010.
‡ Time after intervention represents months beginning after July 2010 to September 2012.
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though there were no formal changes in the National Compre-
hensive Care Network Guidelines regarding the use of
bevacizumab among patients with breast cancer during our
study time frame, it is possible that less formal communications
were occurring among oncologists that shaped prescribing prac-
tices, among other factors.
A third potential explanation for a lack in observed variation
across payers is that commercial payers varied in their use and
implementation of coverage restrictions. For example, in a pre-
vious study, Conti et al24 reported that two large commercial
payers indicated that they did not change coverage policies for
bevacizumab as a result of the FDA’s regulatory actions. In
addition, among plans that intended to change coverage, cov-
erage restrictions may not have been fully implemented because
of public outcry and the negative publicity that surrounded
initial efforts to restrict access to bevacizumab for breast cancer.
Blue Shield of California and the Medicare local contractor,
Palmetto GBA, who announced plans to restrict coverage, both
quickly reversed course after the negative publicity that sur-
rounded these decisions.13,15,23 Importantly, declines in bev-
acizumab use for breast cancer were observed before the
announced coverage policy changes, suggesting that these
events would likely have little impact on use.
There are many reasons why insurers, Medicare, and partic-
ularly the regional contractors might have difficulty imple-
menting a change in coverage policies in this setting.34 First,
bevacizumab is a product that is approved for treating multiple
cancers and, as such, was not being removed from the market-
place with the regulatory actions. Instead, the labeled indication
specific to breast cancer was removed. Given that physicians
may use prescription drug products for off-label indications, it
would be difficult for insurers to completely eliminate bevaci-
zumab’s use for breast cancer if the clinical community still
believed that it was a safe and effective product for their pa-
tients, although, admittedly, physicians would risk having such
claims denied by Medicare or other payers. Second, within
Medicare there are two mechanisms for affecting coverage pol-
icy: local coverage determinations and national determinations.
The case of bevacizumab illustrates how the two policies may
conflict. Although in January 2011, Palmetto GBA issued a
local coverage determination that limited coverage for bevaci-
zumab, CMS later issued a national coverage determination, in
November 2011, that declared continued coverage of bevaci-
zumab. Presumably, the national determination would super-
sede the local coverage determination, causing Palmetto GBA
to change its policies; however, whether such a reversal would
affect changes in behavior would presume that local coverage
determinations were effectively implemented. Foote and
Town34 document several factors that may make it difficult for
regional contractors to ensure that their own local coverage
determinations are followed, including inability to apply local
coverage determinations at the point of payment because of the
lack of data that are necessary to evaluate the claim and a lack of
incentives and infrastructure to enforce coverage policies.
There are several important limitations to note. We did not
have any information on individual patient and provider char-
acteristics, including tumor stage, grade, hormone receptor sta-
tus, or line of therapy, which limited our ability to model
whether other patient, provider-level, or disease characteristics
drove bevacizumab discontinuation. Although our data do not
allow for evaluation of receipt of treatment by stage, a previous
study on the topic reports that the majority of bevacizumab use
was for metastatic indications and that changes in use were not
significantly different by tumor stage.24 We also lacked data on
patient and physician decision making or beliefs about bevaci-
zumab’s safety and effectiveness and the setting in which care
was received. It is possible that smaller or privately owned prac-
tices are more financially vulnerable and thus react more
quickly to anticipated coverage changes. In a previous study we
found earlier declines in bevacizumab use among private prac-
tices, which may support this anticipatory behavior.24 We also
only observed outpatient medical claims for bevacizumab,
which could underestimate use overall if bevacizumab were re-
imbursed through inpatient or pharmacy claims or used in clin-
ical trials. Although nearly all breast cancer chemotherapy is
delivered in outpatient settings,35 providers might have in-
creased their use of bevacizumab in the inpatient setting or in
clinical trials to minimize financial risks to their practices. In
addition, our time series only included the period from 2007
through 2012, so changes in bevacizumab use before 2007 are
not evident in our data. Next, using trends in bevacizumab use
for lung cancer as a negative control may be inappropriate if
there were other factors that influenced bevacizumab use for
lung cancer during the study period. We observed only small
changes in the use of bevacizumab for lung cancer during this
time period. We compared breast cancer use with lung cancer
use as a sensitivity analysis, rather than a primary analysis, given
the potential concerns regarding differences in the use of bev-
acizumab across cancer sites. Finally, we lacked data on actual
insurance coverage policies that were in place, coverage gener-
osity, and other market-level factors that may have influenced
product use outside of the regulatory communications.
In conclusion, bevacizumab use declined rapidly and consis-
tently among women with breast cancer who were commer-
cially insured and Medicare insured (across areas with
potentially varying coverage policies) after concerns were stated
regarding the efficacy and safety of the product for treating
breast cancer. Given the timing and consistency of the declines
that were observed across payers, it is likely that physician de-
cision making (either related to perceptions of a lack of drug
benefit or coverage concerns), rather than payer-specific poli-
cies, drove reductions in bevacizumab use for breast cancer.
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Appendix
Table A1. Baseline Characteristics of Chemotherapy Users by Cancer Type







Medicare local coverage area, %
CGS Administrators, LLC 5.7 6.7
Cahaba Government Benefit Administrators 6.7 6.8
California 10.1 6.8
First Coast Service Options 8.6 11.3
National Government Services 10.9 11.0
NHIC 1.5 1.8
Noridian Healthcare Solutions 6.9 6.4
Novita Solutions 29.0 27.5
Palmetto GBA 10.3 10.3
Wisconsin Physicians Service Insurance Corporation 10.3 11.4
NOTE. Source: IMS Health LifeLink from January 2007 to September 2012, IMS Health. All rights reserved.
Abbreviation: SD, standard deviation.
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